A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months

A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.

The purpose of this study is to describe changes in the intensity of specific endometriosis symptoms from baseline pre-surgery to after surgery and subsequent continuous Diphereline (Triptorelin Acetate) treatment for up to 24 weeks.

Inclusion Criteria:

• Patients diagnosed with DIE and having received surgery treatment within one month before inclusion
• Premenopausal women aged >=18 years old.
• Written ICF has been obtained prior to any study-related procedures
• Patient for whom the treating physician already made the decision to treat by Diphereline.
• Patient should be mentally and physically able to express her symptom complaints and answer questions.

Exclusion Criteria:

• Pregnancy or lactation.
• Patients currently on treatment or who have been on therapy with a GnRHa in the last 6 months.
• Premenopausal women who may reach menopause within the 3 years post randomisation.
• Hypersensitivity to Triptorelin or one of the excipients of Triptorelin 3.75mg
• Treatment with another research drug over the last 3 months before the study
• Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.